2-Site Safety Study of Besivance Versus Vigamox Prophylactically in Routine Cataract Surgery

NCT ID: NCT01455233


Title
Phase IV Study: A Prospective Two-Site Study to Evaluate the Safety and Tolerance of Besivance Versus Vigamox Prophylactically Pre and Post Operatively in Subjects Undergoing Routine Cataract Surgery
Purpose
The purpose of this study is to demonstrate that Besivance is equal to Vigamox in safety and tolerance when used prophylactically in subjects undergoing routine cataract surgery.
Details
Subjects will be assigned to receive either Besivance or Vigamox (1:1) to be administered as 1 drop in the study eye 4 times daily starting 3 days prior to cataract surgery and continuing for 7 days post-operatively. Sixty subjects (30 from Ophthalmology Consultants and 30 from Ophthalmology Associates) of any race and either sex, requiring cataract extraction with planned implantation of a posterior chamber intraocular lens.
Conditions
Corneal Health, Cataract Surgery
Keywords
cornea, ocular antibiotic, cataract surgery
Source
Ophthalmology Consultants, Ltd.
Sponsors
Ophthalmology Consultants, Ltd., Ophthalmology Associates, St Louis, Bausch & Lomb Incorporated
Status
Completed
Acronym
STB-01
Last Updated
17 Oct 2011
URL
Official Link
Locations
United States